Table A1.
ITT outcomes comparison with published data (ITT).
| Study | Population | Sample size* | Length of trial | Dosage | % Remission | Mean (SE) change in MADRS | Mean (SE) change in SDS domains |
|---|---|---|---|---|---|---|---|
| Present study | Postpartum women | 17 | 12 weeks | 50–100 mg/day, flexible | 82.4% | −24.4 (2.23) | Social: −3.4 (0.59) Family: −3.9 (0.72) |
| Clayton et al. [2013] | Women 40–70 years | 216 | 8 weeks | 50 mg/day | 23.6% | −15.1 (0.67) | Total only reported |
| Dunlop et al. [2011] | Employed adults | 285 | 12 weeks | 50 mg/day | 40% | Sig. diff from placebo, values not reported | Social: −3.3 (0.2) Family: −3.2 (0.2) |
| Liebowitz et al. [2013] | Adult outpatients | 224 | 8 weeks | 50 mg/day | 17% | −10.8 (0.63) | Social: −1.4 (0.18) Family: −1.2 (0.17) |
| Thase et al. [2009] | Pooled data of 9 RCTs on adult outpatients | 312 | 8 weeks | 50 mg/day | 45% | −15.8 (0.57) | Not measured |
| 411 | 8 weeks | 100 mg/day | 42% | −15.2 (0.49) |
*
Sample size is limited to ITT patients who received desvenlafaxine.
ITT, intent to treat; MADRS, Montgomery–Åsberg Depression Rating Scale; RCT, randomized controlled trial; SDS, Sheehan Disability Scale; SE, standard error.